P2.03-016 Clinical Utility of Liquid Biopsy for Detecting EGFR T790M Mutation Is Very Limited

Volume: 12, Issue: 11, Pages: S2133 - S2133
Published: Nov 1, 2017
Abstract
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor targeting EGFR T790M acquired resistance mutation, has demonstrated strong clinical activity. Therefore, we have to do a second biopsy to detect T790M when the tumor has progressed. On the other hand, liquid based assays are expected as minimally invasive methods for detecting resistance mutations. Recently, liquid-biopsy for detecting EGFR T790M mutation has been approved by the...
Paper Details
Title
P2.03-016 Clinical Utility of Liquid Biopsy for Detecting EGFR T790M Mutation Is Very Limited
Published Date
Nov 1, 2017
Volume
12
Issue
11
Pages
S2133 - S2133
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.